1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Veralox Therapeutics Acquires Nudge Therapeutics

M&A Deal Summary

Veralox Therapeutics Acquires Nudge Therapeutics

On January 9, 2025, Veralox Therapeutics acquired life science company Nudge Therapeutics

Acquisition Highlights
  • This is Veralox Therapeutics’ 1st transaction in the Life Science sector.
  • This is Veralox Therapeutics’ 1st transaction in the United States.

M&A Deal Summary
Date 2025-01-09
Target Nudge Therapeutics
Sector Life Science
Buyer(s) Veralox Therapeutics
Deal Type Add-on Acquisition

Target

Nudge Therapeutics

United States
Nudge Therapeutics offers AMP-GMP (cGAS) inhibitor compounds.

Search 214,356 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Veralox Therapeutics

Frederick, Maryland, United States
Category Company
Founded 2017
Sector Life Science
DESCRIPTION

Veralox Therapeutics a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway. Veralox Therapeutics was funded in 2017 and is based in Frederick, Maryland.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
Country: United States M&A 1 of 1
Year: 2025 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal